Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.47 |
| ▸ | EGFR | P00533 | 13/20 | 0.47 |
| ▸ | ABL1 | P00519 | 9/20 | 0.47 |
| ▸ | ABL2 | P42684 | 9/20 | 0.47 |
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | CDK1 | P06493 | 5/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | CSK | P41240 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL399678 | 0.84 | SRC (0.49) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL399404 | 0.80 | SRC (0.51) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL401859 | 0.80 | SRC (0.66) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL132511 | 0.80 | SRC (0.71) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL400407 | 0.75 | SRC (0.48) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL402145 | 0.75 | SRC (0.45) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL397596 | 0.74 | SRC (0.43) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL401232 | 0.71 | SRC (0.40) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL400111 | 0.70 | SRC (0.46) | SRCEGFRABL1ABL2KDR | |
| SCHEMBL13840629 | 0.69 | SRC (0.45) | SRCEGFRABL1ABL2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168968-B1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8653268-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130190496-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2013-07-25 | — | — | US | disclosed |
| US-8367826-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120196847-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120077979-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-03-29 | — | — | US | disclosed |
| US-8101613-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2308879-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2305682-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7820662-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2168968-A1 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077979-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | SRC 299/4885EGFR 155/4885ABL1 621/4885 |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | SRC 299/4885EGFR 155/4885ABL1 621/4885 |
| US-20130190496-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | SRC 299/4885EGFR 155/4885ABL1 621/4885 |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | SRC 299/4885EGFR 155/4885ABL1 621/4885 |
| US-20120196847-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | SRC 299/4885EGFR 155/4885ABL1 621/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | SRC 299/4885EGFR 155/4885ABL1 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.